- Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance investor.lilly.com
- Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar CNBC
- Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine statnews.com
- Eli Lilly Smashes Views On Back Of Mounjaro, Zepbound Investor’s Business Daily
- Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war Yahoo Finance
Source link
